-
1
-
-
84862501107
-
The CRM1 nuclear export protein in normal development and disease
-
Nguyen KT, Holloway MP, Altura RA (2012) The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 3: 137-151.
-
(2012)
Int J Biochem Mol Biol
, vol.3
, pp. 137-151
-
-
Nguyen, K.T.1
Holloway, M.P.2
Altura, R.A.3
-
2
-
-
84858005605
-
Nuclear export of proteins and drug resistance in cancer
-
Turner JG, Dawson J, Sullivan DM (2012) Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 83: 1021-1032.
-
(2012)
Biochem Pharmacol
, vol.83
, pp. 1021-1032
-
-
Turner, J.G.1
Dawson, J.2
Sullivan, D.M.3
-
3
-
-
61649105802
-
CRM1-mediated nuclear export of proteins and drug resistance in cancer
-
Turner JG, Sullivan DM (2008) CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 15: 2648-2655.
-
(2008)
Curr Med Chem
, vol.15
, pp. 2648-2655
-
-
Turner, J.G.1
Sullivan, D.M.2
-
4
-
-
84866422549
-
NESdb: A database of NES-containing CRM1 cargoes
-
Xu D, Grishin NV, Chook YM (2012) NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell 23: 3673-3676.
-
(2012)
Mol Biol Cell
, vol.23
, pp. 3673-3676
-
-
Xu, D.1
Grishin, N.V.2
Chook, Y.M.3
-
5
-
-
80052230265
-
Ran-dependent nuclear export mediators: A structural perspective
-
Guttler T, Gorlich D (2011) Ran-dependent nuclear export mediators: a structural perspective. EMBO J 30: 3457-3474.
-
(2011)
EMBO J
, vol.30
, pp. 3457-3474
-
-
Guttler, T.1
Gorlich, D.2
-
6
-
-
11844272621
-
Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo
-
DOI 10.1128/MCB.25.2.728-739.2005
-
Daelemans D, Costes SV, Lockett S, Pavlakis GN (2005) Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo. Mol Cell Biol 25: 728-739. (Pubitemid 40096593)
-
(2005)
Molecular and Cellular Biology
, vol.25
, Issue.2
, pp. 728-739
-
-
Daelemans, D.1
Costes, S.V.2
Lockett, S.3
Pavlakis, G.N.4
-
7
-
-
0030924190
-
CRM1 is an export receptor for leucine-rich nuclear export signals
-
DOI 10.1016/S0092-8674(00)80371-2
-
Fornerod M, Ohno M, Yoshida M, Mattaj IW (1997) CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90: 1051-1060. (Pubitemid 27408519)
-
(1997)
Cell
, vol.90
, Issue.6
, pp. 1051-1060
-
-
Fornerod, M.1
Ohno, M.2
Yoshida, M.3
Mattaj, I.W.4
-
8
-
-
84891851776
-
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications
-
Epub ahead of print
-
Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, et al. (2013) CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia Epub ahead of print.
-
(2013)
Leukemia
-
-
Tai, Y.T.1
Landesman, Y.2
Acharya, C.3
Calle, Y.4
Zhong, M.Y.5
-
9
-
-
32644438345
-
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B
-
DOI 10.1182/blood-2005-05-2123
-
Aloisi A, Di Gregorio S, Stagno F, Guglielmo P, Mannino F, et al. (2006) BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood 107: 1591-1598. (Pubitemid 43242398)
-
(2006)
Blood
, vol.107
, Issue.4
, pp. 1591-1598
-
-
Aloisi, A.1
Di, G.S.2
Stagno, F.3
Guglielmo, P.4
Mannino, F.5
Sormani, M.P.6
Bruzzi, P.7
Gambacorti-Passerini, C.8
Saglio, G.9
Venuta, S.10
Giustolisi, R.11
Messina, A.12
Vigneri, P.13
-
11
-
-
58349104143
-
Identification of nuclear export inhibitors with potent anticancer activity in vivo
-
Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, et al. (2009) Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 69: 510-517.
-
(2009)
Cancer Res
, vol.69
, pp. 510-517
-
-
Mutka, S.C.1
Yang, W.Q.2
Dong, S.D.3
Ward, S.L.4
Craig, D.A.5
-
12
-
-
84881323214
-
Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice
-
Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, et al. (2012) Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice. Gastroenterology 144: 447-456.
-
(2012)
Gastroenterology
, vol.144
, pp. 447-456
-
-
Azmi, A.S.1
Aboukameel, A.2
Bao, B.3
Sarkar, F.H.4
Philip, P.A.5
-
13
-
-
84858004491
-
Cytotoxicity of novel, small molecule, CRM1-selective inhibitors of nuclear export (SINE) in colorectal cancer (CRC) cells
-
Draetta GG, Shacham S, Kauffman M, Sandanayaka V, Schechter S, et al. (2011) Cytotoxicity of novel, small molecule, CRM1-selective inhibitors of nuclear export (SINE) in colorectal cancer (CRC) cells. J Clin Oncol 29: e14091.
-
(2011)
J Clin Oncol
, vol.29
-
-
Draetta, G.G.1
Shacham, S.2
Kauffman, M.3
Sandanayaka, V.4
Schechter, S.5
-
14
-
-
84875052270
-
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective antileukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia
-
Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, et al. (2013) KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective antileukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 161: 117-127.
-
(2013)
Br J Haematol
, vol.161
, pp. 117-127
-
-
Etchin, J.1
Sanda, T.2
Mansour, M.R.3
Kentsis, A.4
Montero, J.5
-
15
-
-
84870502798
-
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
-
Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, et al. (2012) Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 120: 4621-4634.
-
(2012)
Blood
, vol.120
, pp. 4621-4634
-
-
Lapalombella, R.1
Sun, Q.2
Williams, K.3
Tangeman, L.4
Jha, S.5
-
16
-
-
84872427339
-
Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC)
-
Abstract 1055
-
McCauley D, Landesman Y, Senapedis W, Kashyap T, Saint-Martin J-R, et al. (2012) Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC). J Clin Oncol 30 Suppl: Abstract 1055.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
McCauley, D.1
Landesman, Y.2
Senapedis, W.3
Kashyap, T.4
Saint-Martin, J.-R.5
-
17
-
-
84865749132
-
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
-
Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, et al. (2012) Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 120: 1765-1773.
-
(2012)
Blood
, vol.120
, pp. 1765-1773
-
-
Ranganathan, P.1
Yu, X.2
Na, C.3
Santhanam, R.4
Shacham, S.5
-
18
-
-
84870887672
-
Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma
-
Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, et al. (2013) Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 41: 67-78 e64.
-
(2013)
Exp Hematol
, vol.41
-
-
Zhang, K.1
Wang, M.2
Tamayo, A.T.3
Shacham, S.4
Kauffman, M.5
-
19
-
-
84873570648
-
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells
-
Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, et al. (2013) Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 27: 66-74.
-
(2013)
Leukemia
, vol.27
, pp. 66-74
-
-
Etchin, J.1
Sun, Q.2
Kentsis, A.3
Farmer, A.4
Zhang, Z.C.5
-
20
-
-
84877601009
-
CRM1 Blockade by Selective Inhibitors of Nuclear Export Attenuates Kidney Cancer Growth
-
Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, et al. (2013) CRM1 Blockade by Selective Inhibitors of Nuclear Export Attenuates Kidney Cancer Growth. J Urol 189: 2317-2326.
-
(2013)
J Urol
, vol.189
, pp. 2317-2326
-
-
Inoue, H.1
Kauffman, M.2
Shacham, S.3
Landesman, Y.4
Yang, J.5
-
21
-
-
12444319243
-
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies
-
London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, et al. (2003) Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 9: 2755-2768. (Pubitemid 36842122)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.7
, pp. 2755-2768
-
-
London, C.A.1
Hannah, A.L.2
Zadovoskaya, R.3
Chien, M.B.4
Kollias-Baker, C.5
Rosenberg, M.6
Downing, S.7
Post, G.8
Boucher, J.9
Shenoy, N.10
Mendel, D.B.11
McMahon, G.12
Cherrington, J.M.13
-
22
-
-
0344629819
-
Proof of Target for SU11654: Inhibition of KIT Phosphorylation in Canine Mast Cell Tumors
-
Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, et al. (2003) Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 9: 5729-5734. (Pubitemid 37499497)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.15
, pp. 5729-5734
-
-
Pryer, N.K.1
Lee, L.B.2
Zadovaskaya, R.3
Yu, X.4
Sukbuntherng, J.5
Cherrington, J.M.6
London, C.A.7
-
23
-
-
66149168682
-
Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma
-
Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GH, et al. (2009) Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clin Cancer Res 15: 3503-3510.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3503-3510
-
-
Vail, D.M.1
Thamm, D.H.2
Reiser, H.3
Ray, A.S.4
Wolfgang, G.H.5
-
24
-
-
77955625479
-
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
-
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, et al. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107: 13075-13080.
-
(2010)
Proc Natl Acad Sci U S a
, vol.107
, pp. 13075-13080
-
-
Honigberg, L.A.1
Smith, A.M.2
Sirisawad, M.3
Verner, E.4
Loury, D.5
-
25
-
-
80455174301
-
Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
-
London CA, Bear MD, McCleese J, Foley KP, Paalangara R, et al. (2011) Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer. PLoS One 6: e27018.
-
(2011)
PLoS One
, vol.6
-
-
London, C.A.1
Bear, M.D.2
McCleese, J.3
Foley, K.P.4
Paalangara, R.5
-
26
-
-
84862743178
-
CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: A tool for in vitro preclinical studies with primary B-cell malignancies
-
Ito D, Frantz AM, Williams C, Thomas R, Burnett RC, et al. (2012) CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leuk Lymphoma 53: 1390-1398.
-
(2012)
Leuk Lymphoma
, vol.53
, pp. 1390-1398
-
-
Ito, D.1
Frantz, A.M.2
Williams, C.3
Thomas, R.4
Burnett, R.C.5
-
27
-
-
22244458900
-
CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma
-
DOI 10.1354/vp.42-4-468
-
Jubala CM, Wojcieszyn JW, Valli VE, Getzy DM, Fosmire SP, et al. (2005) CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet Pathol 42: 468-476. (Pubitemid 40993857)
-
(2005)
Veterinary Pathology
, vol.42
, Issue.4
, pp. 468-476
-
-
Jubala, C.M.1
Wojcieszyn, J.W.2
Valli, V.E.O.3
Getzy, D.M.4
Fosmire, S.P.5
Coffey, D.6
Bellgrau, D.7
Modiano, J.F.8
-
28
-
-
77952959216
-
Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma
-
Rutgen BC, Hammer SE, Gerner W, Christian M, de Arespacochaga AG, et al. (2010) Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk Res 34: 932-938.
-
(2010)
Leuk Res
, vol.34
, pp. 932-938
-
-
Rutgen, B.C.1
Hammer, S.E.2
Gerner, W.3
Christian, M.4
De Arespacochaga, A.G.5
-
29
-
-
84862993855
-
Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model
-
Rutgen BC, Willenbrock S, Reimann-Berg N, Walter I, Fuchs-Baumgartinger A, et al. (2012) Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model. PLoS One 7: e40078.
-
(2012)
PLoS One
, vol.7
-
-
Rutgen, B.C.1
Willenbrock, S.2
Reimann-Berg, N.3
Walter, I.4
Fuchs-Baumgartinger, A.5
-
30
-
-
0024399987
-
A possible autocrine role for interleukin-6 in two lymphoma cell lines
-
Yee C, Biondi A, Wang XH, Iscove NN, de Sousa J, et al. (1989) A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 74: 798-804. (Pubitemid 19208825)
-
(1989)
Blood
, vol.74
, Issue.2
, pp. 798-804
-
-
Yee, C.1
Biondi, A.2
Wang, X.H.3
Iscove, N.N.4
De Sousa, J.5
Aarden, L.A.6
Wong, G.G.7
Clark, S.C.8
Messner, H.A.9
Minden, M.D.10
-
31
-
-
0025936536
-
Regulation of interleukin-6 expression in the lymphoma cell line OCI-LY3
-
Yee CS, Messner HA, Minden MD (1991) Regulation of interleukin-6 expression in the lymphoma cell line OCI-LY3. J Cell Physiol 148: 426-429. (Pubitemid 21926078)
-
(1991)
Journal of Cellular Physiology
, vol.148
, Issue.3
, pp. 426-429
-
-
Yee, C.S.1
Messner, H.A.2
Minden, M.D.3
-
32
-
-
23744437996
-
c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells
-
DOI 10.1182/blood-2004-10-3819
-
Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, et al. (2005) c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 106: 1382-1391. (Pubitemid 41129605)
-
(2005)
Blood
, vol.106
, Issue.4
, pp. 1382-1391
-
-
Gururajan, M.1
Chui, R.2
Karuppannan, A.K.3
Ke, J.4
Jennings, C.D.5
Bondada, S.6
-
33
-
-
0025514349
-
Establishment of two dog mastocytoma cell lines in continuous culture
-
DeVinney R, Gold WM (1990) Establishment of two dog mastocytoma cell lines in continuous culture. Am J Respir Cell Mol Biol 3: 413-420.
-
(1990)
Am J Respir Cell Mol Biol
, vol.3
, pp. 413-420
-
-
DeVinney, R.1
Gold, W.M.2
-
34
-
-
77956638515
-
Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro
-
McMahon MB, Bear MD, Kulp SK, Pennell ML, London CA (2010) Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro. Am J Vet Res 71: 799-808.
-
(2010)
Am J Vet Res
, vol.71
, pp. 799-808
-
-
McMahon, M.B.1
Bear, M.D.2
Kulp, S.K.3
Pennell, M.L.4
London, C.A.5
-
35
-
-
17644374190
-
Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas
-
DOI 10.1007/s00335-004-2441-x
-
Shelly S, Chien MB, Yip B, Kent MS, Theon AP, et al. (2005) Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas. Mamm Genome 16: 211-217. (Pubitemid 40569197)
-
(2005)
Mammalian Genome
, vol.16
, Issue.3
, pp. 211-217
-
-
Shelly, S.1
Chien, M.B.2
Yip, B.3
Kent, M.S.4
Theon, A.P.5
McCallan, J.L.6
London, C.A.7
-
36
-
-
85048701331
-
Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1
-
Epub ahead of print
-
(2011) Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol Epub ahead of print.
-
(2011)
Vet Comp Oncol
-
-
-
37
-
-
75249085780
-
Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a Veterinary Cooperative Oncology Group (VCOG) consensus document
-
Vail DM, Michels GM, Khanna C, Selting KA, London CA (2010) Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 8: 28-37.
-
(2010)
Vet Comp Oncol
, vol.8
, pp. 28-37
-
-
Vail, D.M.1
Michels, G.M.2
Khanna, C.3
Selting, K.A.4
London, C.A.5
-
38
-
-
80051750421
-
Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer
-
Lynch S, Savary-Bataille K, Leeuw B, Argyle DJ (2011) Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer. Vet Comp Oncol 9: 172-182.
-
(2011)
Vet Comp Oncol
, vol.9
, pp. 172-182
-
-
Lynch, S.1
Savary-Bataille, K.2
Leeuw, B.3
Argyle, D.J.4
-
39
-
-
0030880605
-
Small sample inference for fixed effects from restricted maximum likelihood
-
DOI 10.2307/2533558
-
Kenward MG, Roger JH (1997) Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53: 983-997. (Pubitemid 27391027)
-
(1997)
Biometrics
, vol.53
, Issue.3
, pp. 983-997
-
-
Kenward, M.G.1
Roger, J.H.2
-
40
-
-
84866414249
-
Sequence and structural analyses of nuclear export signals in the NESdb database
-
Xu D, Farmer A, Collett G, Grishin NV, Chook YM (2012) Sequence and structural analyses of nuclear export signals in the NESdb database. Mol Biol Cell 23: 3677-3693.
-
(2012)
Mol Biol Cell
, vol.23
, pp. 3677-3693
-
-
Xu, D.1
Farmer, A.2
Collett, G.3
Grishin, N.V.4
Chook, Y.M.5
-
41
-
-
0030831534
-
CRM1 is responsible for intracellular transport mediated by the nuclear export signal
-
DOI 10.1038/36894
-
Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, et al. (1997) CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390: 308-311. (Pubitemid 27513316)
-
(1997)
Nature
, vol.390
, Issue.6657
, pp. 308-311
-
-
Fukuda, M.1
Asano, S.2
Nakamura, T.3
Adachi, M.4
Yoshida, M.5
Yanagida, M.6
Nishida, E.7
-
42
-
-
33845611951
-
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
-
DOI 10.1016/j.cell.2006.12.007, PII S0092867406015972
-
Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127: 1323-1334. (Pubitemid 44960417)
-
(2006)
Cell
, vol.127
, Issue.7
, pp. 1323-1334
-
-
Martins, C.P.1
Brown-Swigart, L.2
Evan, G.I.3
-
43
-
-
33846899456
-
Restoration of p53 function leads to tumour regression in vivo
-
DOI 10.1038/nature05541, PII NATURE05541
-
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665. (Pubitemid 46232887)
-
(2007)
Nature
, vol.445
, Issue.7128
, pp. 661-665
-
-
Ventura, A.1
Kirsch, D.G.2
McLaughlin, M.E.3
Tuveson, D.A.4
Grimm, J.5
Lintault, L.6
Newman, J.7
Reczek, E.E.8
Weissleder, R.9
Jacks, T.10
-
44
-
-
80053619765
-
CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity
-
Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, et al. (2011) CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 118: 3922-3931.
-
(2011)
Blood
, vol.118
, pp. 3922-3931
-
-
Sakakibara, K.1
Saito, N.2
Sato, T.3
Suzuki, A.4
Hasegawa, Y.5
-
45
-
-
84879566083
-
Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas
-
Azmi AS, Al-Katib A, Aboukameel A, McCauley D, Kauffman M, et al. (2013) Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. Haematologica 98: 1098-1106.
-
(2013)
Haematologica
, vol.98
, pp. 1098-1106
-
-
Azmi, A.S.1
Al-Katib, A.2
Aboukameel, A.3
McCauley, D.4
Kauffman, M.5
-
46
-
-
84880069167
-
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF mutant melanoma
-
Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, et al. (2013) CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF mutant melanoma. Mol Cancer Ther 12: 1171-1179.
-
(2013)
Mol Cancer Ther
, vol.12
, pp. 1171-1179
-
-
Salas Fragomeni, R.A.1
Chung, H.W.2
Landesman, Y.3
Senapedis, W.4
Saint-Martin, J.R.5
|